Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Alpha Tau Medical Ltd. Warrant (DRTSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: DRTSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.27% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 |
52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.17% | Return on Equity (TTM) -47.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 47275829 |
Shares Outstanding - | Shares Floating 47275829 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alpha Tau Medical Ltd. Warrant
Company Overview
History and Background
Alpha Tau Medical Ltd. is a clinical-stage company focused on developing and commercializing its proprietary diffusion-limited alpha-therapy (DLAT) technology for cancer treatment. The company was founded with the aim of providing a novel, targeted radiation therapy. Significant milestones include the development of its Diffusing Alpha-Emitters Radiation Therapy (DART) platform and progress in clinical trials.
Core Business Areas
- DLAT Technology Development: Focuses on research, development, and clinical trials of its Diffusing Alpha-Emitters Radiation Therapy (DART) platform, a novel approach to cancer treatment utilizing alpha-emitting isotopes that diffuse into tumor tissue.
- Clinical Trials and Regulatory Approval: Engaged in conducting clinical studies across various cancer types and working towards obtaining regulatory approvals for its DART technology.
- Commercialization Strategy: Developing plans for the eventual commercialization and widespread adoption of its DART cancer treatment.
Leadership and Structure
Alpha Tau Medical Ltd. is led by a management team with expertise in oncology, radiation physics, and biotechnology. The company operates as a clinical-stage biotechnology firm with a focus on R&D and clinical development.
Top Products and Market Share
Key Offerings
- Product Name 1: Diffusing Alpha-Emitters Radiation Therapy (DART) Platform. This is a novel cancer treatment modality using targeted alpha-emitters. Market share data is not applicable at this stage as it is an investigational technology. Competitors include companies developing other forms of radiation therapy, immunotherapy, and targeted drug therapies.
Market Dynamics
Industry Overview
The oncology market is characterized by continuous innovation in treatment modalities, including radiation therapy, immunotherapy, and targeted therapies. There is a significant unmet need for more effective and less toxic cancer treatments.
Positioning
Alpha Tau Medical Ltd. is positioning itself as a pioneer in diffusion-limited alpha-therapy, offering a potentially differentiated approach to localized cancer treatment with reduced side effects compared to conventional radiation. Its competitive advantage lies in the unique mechanism of its DART platform.
Total Addressable Market (TAM)
The global oncology market is vast and continues to grow, driven by an aging population, increasing cancer incidence, and advancements in treatment. Alpha Tau Medical is targeting specific cancer indications within this broad market, aiming to capture a share of the market for localized cancer treatments.
Upturn SWOT Analysis
Strengths
- Novel DART technology with potential for improved efficacy and reduced side effects.
- Strong scientific foundation and intellectual property.
- Experienced management team.
Weaknesses
- Clinical-stage company, thus high development risk.
- Limited commercial track record.
- Dependence on successful clinical trial outcomes and regulatory approvals.
Opportunities
- Expanding applications of DLAT across various cancer types.
- Potential for strategic partnerships and collaborations.
- Growing demand for innovative cancer therapies.
Threats
- Failure to achieve positive clinical trial results.
- Regulatory hurdles and delays.
- Competition from established and emerging cancer treatments.
- Funding challenges common to biotech startups.
Competitors and Market Share
Key Competitors
- Novocure Limited (NVCR)
- Varian Medical Systems, Inc. (now part of Siemens Healthineers)
- RaySearch Laboratories AB (publ) (Sweden-based, but a global competitor in radiation oncology software)
Competitive Landscape
Alpha Tau Medical's advantages lie in its novel DLAT approach. However, it faces competition from established players in radiation therapy, as well as companies developing other innovative oncology treatments like immunotherapies and targeted drugs. The key disadvantage is its early-stage development status.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by scientific advancements, progression through pre-clinical and early-stage clinical trials, and fundraising efforts.
Future Projections: Future growth is contingent on successful clinical outcomes, regulatory approvals, and effective commercialization of its DART technology. Projections are highly speculative and depend on the successful transition from clinical development to market.
Recent Initiatives: Key initiatives include ongoing clinical trials for various cancer indications, potential expansion of its research team, and engagement with regulatory bodies.
Summary
Alpha Tau Medical Ltd. is a promising clinical-stage company with a novel DLAT technology for cancer treatment. Its key strength lies in its DART platform's potential for improved efficacy and reduced side effects. However, it faces significant risks inherent in clinical development, including trial failures and regulatory hurdles. The company needs to successfully navigate these challenges and secure substantial funding to bring its technology to market, facing strong competition from established oncology players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings)
- Financial news outlets
- Industry analysis reports
Disclaimers:
This JSON data is for informational purposes only and does not constitute financial advice. Information is based on publicly available data and may not be exhaustive or up-to-date. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Tau Medical Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-08 | CEO & Chairman Mr. Uzi Sofer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.alphatau.com |
Full time employees 125 | Website https://www.alphatau.com | ||
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.